tirzepatide for menopause symptoms New research from a Mayo Clinic–led study suggests that postmenopausal women using hormone therapy may experience greater weight loss when treated with tirzepatide, a GLP-1–based medication overweight and obesity. In Combination of Hormone Therapy and

It was so freeing only having 1 main journal to house my innermost thoughts and creative ideas

When activated therapeutically, the glucagon receptor appears to increase energy expenditure and promote fat oxidation

Side-by-side evidence Outcomes where both peptides have published data

These results may be compared with those of a post hoc analysis of the LEADER trial, which demonstrated similar incidence rates of MACE in the liraglutide vs placebo group in subjects with a relatively low baseline CV risk (defined as isolated CKD, hypertension with left ventricular hypertrophy, New York Heart Association Class II or III heart failure, and left ventricular systolic or diastolic dysfunction) [37]

This means bones can break easily, even from small injuries or accidents